Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study
Author: Nolan, B.J.
Frydman, A.S.
Leemaqz, S.Y.
Carroll, M.
Grossmann, M.
Zajac, J.D.
Cheung, A.S.
Citation: Endocrine Connections, 2022; 11(5):e220170-1-e220170-8
Publisher: BioScientifica
Issue Date: 2022
ISSN: 2049-3614
Statement of
Brendan J Nolan, Aviva S Frydman, Shalem Y Leemaqz, Meg Carroll, Mathis Grossmann, Jeffrey D Zajac and Ada S Cheung
Abstract: Objective: The role of micronised progesterone in hormone regimens for transgender individuals undergoing feminising hormone therapy remains uncertain. We aimed to determine the effect of oral micronised progesterone on sleep quality, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy. Design: Prospective case–control study. Twenty-three transgender individuals on stable oestradiol treatment newly commencing 100 mg oral progesterone (n = 23) and controls continuing standard care (n = 19) were assessed over 3 months. Methods: Pittsburgh Sleep Quality Index (PSQI), Kessler psychological distress scale (K10), and Tanner stage to assess breast development were assessed at 0 and 3 months. Nonparametric analysis of covariance was used to compare difference s between groups. Results: Compared with controls over 3 months, there was no difference i n PSQI (P = 0.35), K10 (P = 0.64), or Tanner stage (P = 0.42). There was no significant difference in the proportion of individuals with clinically significant improvement in PSQI (25% vs 22%, P = 0.84). One individual had a significant deterioration in psychological distress that improved following the cessation of progesterone. Conclusions: Low-dose progesterone was not associated with changes in sleep quality, psychological distress, or breast development over 3 months follow-up, though there was significant inter-individual variability. Larger, placebo-controlled trials are required to further evaluate different doses of progesterone in feminising hormone therapy regimens.
Keywords: progesterone
Rights: © 2022 The authors. Published by Bioscientifica Ltd. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DOI: 10.1530/EC-22-0170
Grant ID:
Appears in Collections:Paediatrics publications

Files in This Item:
File Description SizeFormat 
hdl_136549.pdfPublished version707.49 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.